Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05924776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Plasmodium Immunotherapy for Advanced Ovarian Cancer

StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 3 to 2v8
  2. Start date: Apr 20, 2024 to Jul 20, 2024
    • Secondary endpoints: details revised at 1 of 3 entries
    v7
  3. Start date: Dec 20, 2023 to Apr 20, 2024v6
  4. Start date: Aug 20, 2023 to Dec 20, 2023v5
  5. Lead sponsor: CAS Lamvac Biotech Co., Ltd. to CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.v4
Show 2 earlier versionsHide 2 earlier versions
  1. Eligibility criteria shortened, about 7 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site contact updated
    • Study description shortened, about 2 words
    v3
  2. Study title shortened, about 3 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer. Each patient is inoculated with Plasmodium vivax 1-5 × 10\^6, observe the time when the parasite is detected in the peripheral blood of the subjects after the inoculation of Plasmodium, the change of the parasite density in the peripheral blood of the whole treatment cycle and the control effect of the drug on the parasite density, the main clinical symptoms and signs, laboratory test indicators, immunological test indicators and changes in the quality of life. To evaluate the safety and tolerance of the subjects to Plasmodium immunotherapy, as well as the changes of tumor related indicators and immunological indicators.
Trial Details
NCT Number NCT05924776
Lead Sponsor CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Collaborators: The Third Affiliated Hospital of Southern Medical University
Conditions
(from sponsor)		 Advanced Ovarian Cancer
Related terms Malaria, Vivax
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov